Arcutis to Present at Upcoming Investor Conference
11 November 2021 - 12:02AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing meaningful
innovations in immuno-dermatology to address the urgent needs of
patients living with immune-mediated dermatological diseases and
conditions, today announced that Arcutis management will
participate in an upcoming investor conference in November.
Details for the company’s participation are as follows:
- Guggenheim 3rd Annual
Neuro/Immunology Conference (Virtual)Fireside Chat
Date: Tuesday, November 16, 2021Fireside Chat
Time: 1:00 p.m. EST
Webcasts for this conference may be accessed at the “Events
& Presentations” section of the Company’s website
at https://investors.arcutis.com/events-and-presentations. The
replay of the webcast will be available on the Arcutis website
following the conference.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is a medical dermatology company that champions
meaningful innovation to address the urgent needs of patients
living with immune-mediated dermatological diseases and conditions.
With a commitment to solving the most persistent patient challenges
in dermatology, Arcutis harnesses our unique dermatology
development platform coupled with our dermatology expertise to
build differentiated therapies against biologically validated
targets. Arcutis’ dermatology development platform includes a
robust pipeline with multiple clinical programs for a range of
inflammatory dermatological conditions, with one NDA submission
filed with the FDA and three Phase 3 clinical data readouts
anticipated by the end of 2022. The company’s lead program, topical
roflumilast, has the potential to advance the standard of care for
plaque psoriasis, atopic dermatitis, scalp psoriasis, and
seborrheic dermatitis. For more information,
visit www.arcutis.com or follow Arcutis on LinkedIn and
Twitter.
Forward-Looking StatementsThis press release
contains "forward-looking" statements, including, among others,
statements regarding the potential for roflumilast to revolutionize
the standard of care in plaque psoriasis and other inflammatory
dermatological conditions. These statements involve substantial
known and unknown risks, uncertainties and other factors that may
cause our actual results, levels of activity, performance, or
achievements to be materially different from the information
expressed or implied by these forward-looking statements and you
should not place undue reliance on our forward-looking statements.
Risks and uncertainties that may cause our actual results to differ
include risks inherent in the clinical development process and
regulatory approval process, the timing of regulatory filings, and
our ability to defend our intellectual property. For a further
description of the risks and uncertainties applicable to our
business, see the "Risk Factors" section of our Form 10-K filed
with U.S. Securities and Exchange Commission (SEC) on February 16,
2021, as well as any subsequent filings with the SEC. We undertake
no obligation to revise or update information herein to reflect
events or circumstances in the future, even if new information
becomes available.
Contacts:
MediaAmanda Sheldon, Head of Corporate
Communications(805) 418-5006asheldon@arcutis.com
InvestorsEric McIntyre, Head of Investor
Relations(805) 418-5006emcintyre@arcutis.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024